A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.

Key facts

Study ID

NCT01429740

Run by

Pfizer

People needed

29

Starts

2011-08-01

Expected to finish

2011-12-01

Last updated by the study team

2012-04-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• male or female of non-childbearing potential,

You may not qualify if…

• Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.